Pill research results in new guidance from CSM.
D001695:Biology; D003142:Communication; D003257:Consumer Product Safety; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003695:Delivery of Health Care; D003710:Demography; D017135:Desogestrel; D019049:Developed Countries; D004194:Disease; D004617:Embolism; D005060:Europe; D005069:Evaluation Studies as Topic; D005193:Family Planning Services; D005843:Geography; D006262:Health; D006282:Health Personnel; D019359:Knowledge; D016912:Levonorgestrel; D009640:Norethindrone; D011153:Population; D011634:Public Health; D012111:Residence Characteristics; D018570:Risk Assessment; D012307:Risk Factors; D012449:Safety; D013923:Thromboembolism; D013927:Thrombosis; D006113:United Kingdom; D014652:Vascular Diseases
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D016912:Levonorgestrel; D017135:Desogestrel; D009640:Norethindrone
Biology; Communication; Community; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Delivery Of Health Care; Desogestrel; Developed Countries; Diseases; Embolism; Europe; Evaluation; Family Planning; Geographic Factors; Gestodene; Health; Health Personnel; Information Distribution; Knowledge; Levonorgestrel; Norethindrone; Northern Europe; Oral Contraceptives; Population; Product Approval; Public Health; Residence Characteristics; Risk Assessment; Risk Factors; Safety; Spatial Distribution; Thromboembolism; Thrombosis; United Kingdom; Vascular Diseases